 | |
| Clinical data | |
|---|---|
| Trade names | Ensacove |
| Other names | X-396 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625004 |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.306.918 |
| Chemical and physical data | |
| Formula | C26H27Cl2FN6O3 |
| Molar mass | 561.44 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ensartinib, sold under the brand nameEnsacove, is ananti-cancer medication used for the treatment ofnon-small cell lung cancer.[1] Ensartinib is anAnaplastic lymphoma kinase (ALK) inhibitor used as the salt ensartinib hydrochloride.[1] It is takenby mouth.[1]
The most common adverse reactions include rash, musculoskeletal pain, constipation, cough, pruritis, nausea, edema, pyrexia, and fatigue.[2]
Ensartinib was approved for medical use in the United States in December 2024.[1][2][3][4]
Ensartinib isindicated for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.[1][2]
Efficacy was evaluated in eXALT3 (NCT02767804), an open-label, randomized, active-controlled, multicenter trial in 290 participants with locally advanced or metastatic ALK-positive non-small cell lung cancer who had not previously received an ALK-targeted therapy.[2] Participants were randomized 1:1 to receive ensartinib or crizotinib.[2]
Ensartinib was approved for medical use in the United States in December 2024.[2][3][5]
Ensartinib is theinternational nonproprietary name.[6]
Ensartinib is sold under the brand name Ensacove.[1][2][3]
This article incorporates text from this source, which is in thepublic domain.